0.5877

2.38% -0.0143

Citius Pharmaceuticals Inc (CTXR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CTXR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.602

Aprire:

$0.602

Volume 24 ore:

299.62K

Relative Volume:

0.55

Capitalizzazione di mercato:

$16.13M

Reddito:

$5.61M

Utile/perdita netta:

$-55.45M

Rapporto P/E:

-0.2287

EPS:

-2.5703

Flusso di cassa netto:

$-42.35M

1 W Prestazione:

-2.39%

1M Prestazione:

-5.59%

6M Prestazione:

-28.01%

1 anno Prestazione:

-48.90%

Intervallo 1D:

$0.58

$0.6099

Intervallo di 1 settimana:

$0.563

$0.6143

Portata 52W:

$0.4687

$2.19

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Nome

Citius Pharmaceuticals Inc

Settore

Healthcare (1074)

Industria

Biotechnology (600)

Telefono

(908) 967-6676

Indirizzo

11 COMMERCE DRIVE, CRANFORD, NJ

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-18

Ultimi documenti SEC

CTXR's Discussions on Twitter

Compare CTXR vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTXR Citius Pharmaceuticals Inc	0.5877	16.47M	5.61M	-55.45M	-42.35M	-2.5703
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-30	Aggiornamento	D. Boral Capital	Hold → Buy
2021-11-30	Iniziato	Maxim Group	Buy

Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie

Aug 21, 2026

Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Aug 21, 2026

Nasdaq gives Citius (NASDAQ: CTXR) more time before $1 delisting risk - Stock Titan

Aug 21, 2026

Aug 19, 2026

H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com - Investing.com South Africa

Aug 19, 2026

Aug 18, 2026

Citius (CTXR) Market-Day Review: Finishes 1.78% Higher at $0.57 in the Latest Session; Key Levels: the Near-Term Reference Band Stretches From $0.54 to $0.60 in the Available RecordWMA Signal - vinanet.vn

Aug 18, 2026

Aug 16, 2026

Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Clinical Focus Checkpoint Mean? - Kalkine Media

Aug 16, 2026

Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media

Aug 16, 2026

Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus

Aug 16, 2026

CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% While Stock Gains 3.0%Analyst Earnings Estimate - vinanet.vn

Aug 16, 2026

Citius Pharmaceuticals (CTXR) Gains 3% to $0.76 as Buyers Defend SupportBull Pennant - dars.gov.et

Aug 16, 2026

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

Aug 16, 2026

Aug 14, 2026

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Aug 14, 2026

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Aug 14, 2026

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Aug 14, 2026

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - The AI Journal

Aug 14, 2026

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

Aug 14, 2026

CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView

Aug 14, 2026

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Aug 14, 2026

Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026 - marketscreener.com

Aug 14, 2026

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan

Aug 14, 2026

CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView

Aug 14, 2026

Aug 13, 2026

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Aug 13, 2026

Aug 12, 2026

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Aug 12, 2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Aug 12, 2026

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Aug 12, 2026

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Aug 12, 2026

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Aug 12, 2026

Aug 11, 2026

Citius Pharmaceuticals (CTXR) Edges Higher by 1.92%, Maintaining Position Above Key Support at $0.69TWAP Entry - vinanet.vn

Aug 11, 2026

Aug 09, 2026

BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - Mshale

Aug 09, 2026

Aug 08, 2026

CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% as Shares Rise 6.23%Banking Earnings Report - vinanet.vn

Aug 08, 2026

Aug 07, 2026